Abstract 10888: Clinical Outcomes of Novel Aldosterone Synthase Inhibitors (Lorundrostat and Baxdrostat) in Low and High Dose in Uncontrolled Hypertension: A Systematic Review and Meta-Analysis of RCTs
Background: Despite the availability of antihypertensive therapies, uncontrolled and resistant hypertension remains common, possibly driven by inappropriate aldosterone activity. Novel aldosterone synthase inhibitors (ASIs) such as Lorundrostat and Baxdrostat selectively inhibit CYP11B2, offering to reduce aldostero...